---
title: "Lanreotide - Acromegaly"
sidebar: mydoc_sidebar
permalink: db06791-mesh-d000172-1.html
toc: false 
---


Path ID: `DB06791_MESH_D000172_1`
{% include image.html url="images/db06791-mesh-d000172-1.png" file="db06791-mesh-d000172-1.png" alt="db06791-mesh-d000172-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C060347 | lanreotide | Drug |
| MESH:D013004 | Somatostatin | ChemicalSubstance |
| UniProt:P30874 | Somatostatin receptor type 2 | Protein |
| UniProt:P35346 | Somatostatin receptor type 5 | Protein |
| GO:0038169 | Somatostatin receptor signaling pathway | BiologicalProcess |
| MESH:D000172 | Acromegaly | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Lanreotide | CHEMICALLY SIMILAR TO | Somatostatin |
| Somatostatin | INCREASES ACTIVITY OF | Somatostatin Receptor Type 2 |
| Somatostatin | INCREASES ACTIVITY OF | Somatostatin Receptor Type 5 |
| Somatostatin Receptor Type 2 | PARTICIPATES IN | Somatostatin Receptor Signaling Pathway |
| Somatostatin Receptor Type 5 | PARTICIPATES IN | Somatostatin Receptor Signaling Pathway |
| Somatostatin Receptor Signaling Pathway | NEGATIVELY REGULATES | Acromegaly |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB06791](https://go.drugbank.com/drugs/DB06791)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201185/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201185/)
  - [https://en.wikipedia.org/wiki/Lanreotide](https://en.wikipedia.org/wiki/Lanreotide)
